Evidence map›Paper›PMID 39058503›Full record

Trial reportTranslational vision science & technology2024

Long-Term Effects of Intravitreal Ranibizumab Compared With Panretinal Photocoagulation on Optical Coherence Tomography Measured Choroidal Thickness and Vascularity.

Brian Lee, Kristin Josic, Muneeswar G Nittala, Swetha B Velaga, Ayesha Karamat, Sowmya Srinivas, Federico Corvi, Gagan Singh, Srinivas Sadda, Jennifer K Sun and 2 more

Abstract readComparative StudyRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Translational vision science & technology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Brian LeeDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Kristin JosicJaeb Center for Health Research, Tampa, FL, USA.
Muneeswar G NittalaDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Swetha B VelagaDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Ayesha KaramatDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Sowmya SrinivasDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Federico CorviDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Gagan SinghDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Srinivas SaddaDoheny Eye Institute, University of California, Los Angeles, CA, USA.
Jennifer K SunDRCR Retina Network, Tampa, FL, USA.
Michael IpDoheny Eye Institute, University of California, Los Angeles, CA, USA.
DRCR Retina Network

Funding

DIABETIC RETINOPATHY CLINICAL RESEARCH NETWORK COORDINATING CENTERU10EY014231 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI GLASSMAN, ADAM R · 2002 to 2018
$91.2M
DRCR Retina NetworkUG1EY014231 · NEI · JAEB CENTER FOR HEALTH RESEARCH, INC. · PI Adam R Glassman, DANIEL F MARTIN · 2019 to 2026
$75.4M
NEI NIH HHS U10 EY014231NEI NIH HHS UG1 EY014231
6 · The paper itself

Abstract

Purpose: Compare choroidal changes in ranibizumab versus panretinal photocoagulation (PRP)-treated eyes with proliferative diabetic retinopathy (PDR). Methods: DRCR Retina Network Protocol S post hoc analysis evaluated optical coherence tomography change in choroidal thickness (subfoveal and 3mm superior and inferior to the fovea) through five years; choroidal vascularity index (CVI) was assessed at baseline and one year. Mixed linear models for choroidal change included adjustments for the baseline choroidal value and age. Results: This study included 328 eyes (158 ranibizumab and 170 PRP) from 256 participants (88 ranibizumab and 95 PRP eyes at five years). Mean change in choroidal thickness from baseline to five years at the fovea was -12 µm in ranibizumab versus -8 µm in PRP (difference [95% confidence interval]: -4 [-18 to 10], P = 0.57), superior was -14 µm versus -19 µm (difference: 5 [-8 to 17], P = 0.45) and inferior was -26 µm versus -32 µm [difference: 5 (-9 to 20), P = 0.45]; change at all three points within the ranibizumab group, and the superior and inferior points for PRP, were statistically significant (P < .05). Mean change in CVI at one year was -0.02% in ranibizumab versus -0.95% in PRP (difference: 0.93 [-0.35 to 2.21], P = 0.14). Conclusions: In patients with PDR, treatment with ranibizumab versus PRP did not result in statistically significant differences in five-year choroidal thickness or one-year CVI change. Both groups had significant decreases in choroidal thickness at five years. Translational Relevance: Ranibizumab treatment for PDR did not statistically significantly affect choroidal thickness or vascularity differently than PRP.

Indexed as

Angiogenesis InhibitorsChoroidDiabetic RetinopathyIntravitreal InjectionsLaser CoagulationRanibizumabTomography, Optical CoherenceAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedTreatment OutcomeVascular Endothelial Growth Factor AVisual AcuityAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor A

Identifiers

PMID39058503
PMCPMC11282891

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.